Kumar Rajesh, Misra Arup Kumar, Dutta Siddhartha, Gupta Ajay, Kumar Bharat, Charan Jaykaran
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Patna, Bihar, India.
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India.
J Family Med Prim Care. 2022 Jun;11(6):2573-2580. doi: 10.4103/jfmpc.jfmpc_1934_21. Epub 2022 Jun 30.
A significant surge of cases of mucormycosis is seen in individuals with COVID-19 with presence of diabetes mellitus (DM) and usage of corticosteroids. We aim to conduct a systematic analysis of the cases involving presence of mucormycosis and to find out its association with COVID-19, diabetes mellitus, and corticosteroids.
The electronic records of PubMed, Google Scholar, and Science Direct were searched for the case reports and case series that reported mucormycosis in association of COVID-19. The particulars of each case report and case series were retrieved, stored and analyzed.
In this study, 476 cases of mucormycosis were reported. In 346 cases of mucormycosis, the patients were found to be COVID-19 positive. The incidence of diabetes Mellitus (DM) was 67.01%. Corticosteroid was administered in 57.77% of the cases. Mortality was reported in 36.34% of the cases.
An immunosuppressive environment created due to the COVID-19, diabetes mellitus, and extensive use of corticosteroid provide a suitable background for the increased incidence of mucormycosis. The COVID task force should adopt an aggressive multidisciplinary approach to optimize the use of corticosteroids and maintain glucose in the optimal range.
在患有2型糖尿病（DM）且使用皮质类固醇的新型冠状病毒肺炎（COVID-19）患者中，毛霉菌病病例显著激增。我们旨在对涉及毛霉菌病的病例进行系统分析，并找出其与COVID-19、糖尿病和皮质类固醇的关联。
在PubMed、谷歌学术和科学Direct的电子记录中搜索报告与COVID-19相关的毛霉菌病的病例报告和病例系列。检索、存储和分析每个病例报告和病例系列的详细信息。
在本研究中，报告了476例毛霉菌病病例。在346例毛霉菌病病例中，患者被发现新型冠状病毒肺炎检测呈阳性。糖尿病（DM）的发病率为67.01%。57.77%的病例使用了皮质类固醇。36.34%的病例报告了死亡情况。
COVID-19、糖尿病和皮质类固醇的广泛使用所造成的免疫抑制环境为毛霉菌病发病率增加提供了合适的背景。COVID-19特别工作组应采取积极的多学科方法，以优化皮质类固醇的使用，并将血糖维持在最佳范围内。
